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With an estimated worldwide incidence of about 2%1, psoriasis is the most common autoimmune 
disease in the world with about 80 million affected persons, 20 million of whom being affected 
in a moderate to severe way. Though psoriasis is common in people of all ages, it appears more 
Environmental factors, immunology and 
genetics all play an important role in the 
onset of the disease2,3. Due to its chronic 
nature, physical appearance and high 
degree of morbidity, the disease can have 
significant effects on a person's physical 
and mental health as well as social life. 
Typically the condition is characterized by 
the presence of red scaly skin plaques4. 
The histopathological features of psoriasis 
include growth and dilation of the 
superficial blood vessels (redness) and 
hyperplasia of the epidermis (plaques and 
scales). The epidermic hyperplasia is the 
result of a rapid proliferation and maturation 
of keratinocytes resulting in incomplete 
granular keratinocytes and squamous 
comeocytes tenninal differentiation. Thus, 
the squamous keratinocytes retain intact 
nuclei (parakeratosis) and reduce their 
release of extracellular lipids that normally 
are responsible for the adherence of the 
comeocytes. This lack of adherence results 
in the characteristic scale or flakes of the 
psoriatic lesions. 
An understanding of the pathogenesis of 
pSOliasis requires knowledge of the 
immunologic processes occun'ing in the 
skin. Together with the peripheral lymph 
nodes and circulating immunocompetent 
T lymphocytes, a number of 
immunological actions within the skin 
layers, effectively render the skin an 
important lymphoid organ. This collection 
of antigen-presenting cells (APCs), the 
epidermotropic T cells, the dermal 
capillary endothelial cells, cytokine-
synthesizing keratinocytes, and the 
draining lymph nodes form what has 
become known as skin-associated 
lymphoid tissue (SALT). In addition, 
through the effect of different cytokines 
and chemical mediators, other cells such 
as mast cells, tissue macrophages, 
granulocytes, fibroblasts, and dendritic 
cells, interact with one another. 
The cellular physiological picture of 
psoriasis can be split into the induction 
phase and the elicitation phase. During 
the induction phase, APCs in the 
epidermis process antigens (autoantigens 
or bacterial antigens) and once in the 
lymph nodes, present this infOlmation to 
the CD4 helper and CD8 T-cells. An 
frequently in early adulthood. 
Drug 
Methotrexate 
(most widely used 
systemic drug) 
Cyclospor in 
Phototherapy 
(widely used treatment 
in moderate to severe 
psoriasis) 
Mycophcnolatc mofctil 
(also used in prevention 
of organ transplant 
rejection and in the 
treatment of rheumatoid 
arthritis) 
Hydroxyurea 
(mainly used in 
haematological 
malignancies and in 
sickle cell disease) 
Thioguanine 
Liarozolc 
Fumaric acid esters 
Pimecrolimus 
Molecular Action 
• competitive inhibitor of the 
enzyme dihydrofolate reductase 
- inhibits thymidylate synthesis 
• binds cyclophilin, 
(immunosuppressant-binding 
protein). The complex binds to and 
inhibits the enzyme, calcineurin, 
resulting in blockage of signa l 
transduction pathways that are 
dependent on the transcription 
factor, NF-AT (nuclear factor of 
activated T cell s) 
• formation of photoadducts 
with DNA 
• inhibits the enzyme,inosine 
monophosphate dehyrogenase 
• inhibits ribonucleotide 
diphosphate reductase, 
the enzyme that converts 
ribonucleotides to de 
oxyribonucleotide triphosphates 
• chemical analogue of guanine 
and adenosine - incorporated into 
DNA in place of guanine, leading 
to DNA derangement 
• inhibitor of the cytochrome 
P450 pathway 
• induction of preferential 
apoptosis in activated T cells 
through NF- B pathway 
• binds to FKBP-12 protein-
inhibits the enzyme, ca1cineurin 
resulting in blockage of signal 
transduction pathways that are 
dependent on the transcription 
factor, NF-AT (nuclear factor of 
ar.ti vated T cell s) 
Physiological Action 
• inhibits the replication and 
function of T and B cells 
• suppresses the secretion of cytokines 
• suppresses epidermal cell 
• inhibition of the cytokines IL-2 
and IFN-y (i nhibits T-helper cell 
activation and proliferation) 
• direct effect on the proliferation 
of epidermal keratinocytes 
• reduces the dendritic 
(Langerhans) and cytotox ic T cells 
• reduces cytokine secretion 
• inhibits purine synthesis in 
lymphocytes and thus reduces 
lymphocyte proliferation, 
antibody production, and the 
formation of adhesion molecules 
in response to antigenic or 
mitogenic stimulation 
• depresses basal cell 
replication in the epidermis 
• reverses the abnormal keratin 
proliferation in psoriatic plaques 
• inhibits vascu lar proliferation 
in the dermis 
• lowers the neutrophil count in the 
skin with decreased formation of 
pustules and microabscesses in 
psoriatic plaques 
• suppresses lymphocyte and 
keratinocyte proliferation 
• decreases the number of 
CDll+ cells 
• decreases TCAM- l expression 
• decreases keratinocyte proliferation 
• inhibits T-cell activity and causes 
a shift from a Type I helper T cell 
response to a Type 2 helper T cell 
response 
• specific inhibitor of the 
production of proinfiammatory 
cytokines from T cells and 
mast cells 
• reduces proliferation ofT cell s 
after antigen-specific or 
nonspecific stimulation 
Figure 1: Pharmacological action of drugs used in psoriasis 
immune reaction occurs with the 
proliferation and release of both effector 
and memory T cells (elicitation phase). 
Through the release of neutrophil, 
monocyte and keratinocytes chemotactic 
and activating cytokines, these cells 
increase the inflammatory reaction in the 
epidermis. 
continues on page 8 
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The trigger for the abnormally increased 
T-cell infIltration is thought to be either 
due to a dysregulatory response or due 
to the continuous activation of the APCs. 
Bacterial, viral (retrovirus) and 
keratinocyte proteins (autoreactivity) have 
been implicated as the causative antigens. 
From the genetic point of view, psoriasis 
is a genetically heterogenous disorder with 
multiple genes involved as well as complex 
environmental interactions that can explain 
the heterogeneity of both the severity and 
location of the disease manifestation. 
Two main genetic loci on chromosomes 
6p and 17 q have been reported in genome 
scans. The lll.-A-Cw6 phenotype has 
been found to increase the risk of psoriasis 
by about 10 fold. Similarly to other HLA-
linked conditions (eg. Coeliac Disease), 
though the lll.-A locus is an important 
risk factor, the fact that around 10% of 
the population carry the phenotype and 
only 2% have the condition, indicates 
that other genetic/environmental factors 
are at play. In fact, the PSORS 1 locus 
near the lll.-A-C has been estimated to 
account for 30% to 50% of the genetics 
contribution to psoriasis. 
Two regions within chromosome 17q 
have been associated with psoriasis and 
being relatively distant from each other, 
seems to indicate that they have an 
independent effect on the disorder. The 
two genes within the first peak are 
SLC9A3R1 and NAT9 whilst RAPTOR 
has been identifIed within the second 
peak. 
SLC9A3R1 is a scaffold protein, linking 
plasma membrane proteins to the actin 
cytoskeleton in epithelial cells. External 
signals can lead to changes in signal 
transduction and cell growth via this 
protein. Thus disruption of this scaffold, 
could prolong the time that the antigen is 
presented to the T cell receptor, leadin~ to 
prolonged inflammation. The actual DNA 
change, seems to be the loss of a RUNX1 
site lying between the two genes. This 
variant is quite common in the population, 
so the actual associated susceptibility risk 
is low (this is a running theme with other 
variants predisposing to complex disease, 
that is, they are common in the general 
population and thus require additional 
susceptibility factors). RUNX1 is a major 
transcription factor in the development of 
haematopoietic cells. Though the actual 
consequence of loss of this particular 
RUNX1 site is unknown, alterations in 
RUNXl sites in other genes predispose 
to other autoimmune diseases (systemic 
lupus erythematosus and rheumatoid 
arthri tis). 
RAPTOR is a binding and regulatory 
factor of mTOR, a major regulator of T 
Structure Action 
Infliximab 3 MA Anti-TNF-a Neutralizes serum and 
membrane bound TNF-a 
Etanercept 3 FP Human IgGI Fc + TNF-a receptor Combines with TNF-a in serum 
(acts as receptor) 
Efalizumab 2 MA Human IgG + murine variable Blocks interaction of LFA-I 
against CD I1 a subunit of LFA-I with ICAM-I 
Alefacept FP IgG Fc + LFA-3 Blocks T-cell activation by 
interfering with CD2/LFA-3 
interaction 
Figure 2: Currently approved biologies for psoriasis (MA: Monoclonal Antibody; 
FP: Fusion Protein). 
cell function and growth, through the 
cytokine-triggered protein kinase cascade 
that leads to the phosphorylation of the 
eukaryotic initiation factor, PHAS-1, in 
activated T lymphocytes. Rapamycin 
binds to and blocks the function of mTOR, 
leading to immunosuppression. 
Other susceptibility loci for psoriasis 
reside on chromosomes 1q21, 3q21, 4q, 
7p, 8, 11, 16q and 20p. A recent study 
has identified over 1300 altered gene 
expression within lesional skin when 
compared to uninvolved skin.s 
Similar to other disease, the study of 
the genetic pattern in psoriasis can lead 
to the identification of novel 
pathophsyiological biochemical pathways 
and thus help to identify targets for novel 
therapeutics. In addition, a deeper 
understanding of the genetic background 
can also assist in disease prediction, 
prognosis, as well as in the 
pharmacogenomics of psoriasis. TIle latter 
could even lead to the creation of 
personalised therapies. 
Treatment aspects 
As a chronic disease with exacerbations, 
remissions, and recurring lesions, the 
tTt:atlllt:nt options [or Psoriasis depend 
on the extent and severity of the disease, 
safety aspects of systemic agents, 
economic issues, accessibility to 
phototherapy treatment centres and 
quality-of-life issues. Various treatments 
are available and are used either alone or 
in combination. The therapeutic 
mechanism of most traditional drugs can 
be explained through their action on T-
cell function. 
The Biologies 
Biologic or 'Biologic response 
modifiers' is the generic term for a 
group of hormonal, neuroactive and 
immunoreactive compounds that act 
at the cellular level. Whilst derived 
from living material (human or non-
human), they are produced through 
recombinant DNA techniques and 
possess pharmacological activity. 
Biologics include monoclonal 
antibodies, fusion proteins, cytokines, 
lymphokines, and other 
antiproliferative agents. 
The biologics currently approved for 
psoriasis (Figure 2) are either fusion 
proteins or monoclonal antibodies and 
can be divided into three main groups 
based upon their modes of action: 
• Group 1: Reduce the number of 
pathogenic T cells 
• Group 2: Inhibit T-cell activation and 
migration 
• Group 3: Block the activity of 
inflammatory cytokines 
The Future 
Psoriasis is a disorder of chronic T-cell 
stimulation with a genetic predisposition 
in which environmental triggers play a 
major role. With a greater knowledge of 
the molecular pathways responsible for 
both general as well as cutaneous 
immunology, new, highly specific, 
immune-targeting biologic modifiers can 
be developed. ~e would ideally have 
an excellent long tClm safety profile as 
well as being an effective treatment to 
ease most if not all problems associated 
with the disease. 
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